Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Names Directors for Biodefense Unit; PointOne Names New CEO; Compugen Adds a VP; and Others

NEW YORK, Sept. 1 (GenomeWeb News) - Invitrogen has created an advisory board for its Biological Defense Systems, which was created "to respond quickly to the evolving requirements of biodefense research by drawing upon technologies from across Invitrogen's broad portfolio," according to James Gilmore, director of the new division.

Joining the advisory board are:

  • David Franz, chief biological scientist at Midwest Research Institute, Frederick, Md., has been named chairman of the advisory board. Franz is a retired Army colonel and former commander of the US Army Medical Research Institute of Infectious Diseases. He also directs the National Agricultural Biosecurity Center based at Kansas State University.
  • Margaret Hamburg, vice president of biological programs of the Washington, DC-based Nuclear Threat Initiative, has been named a director. Hamburgserved as assistant secretary for planning and evaluation with the US Department of Health and Human Services, where she was the principal policy advisor. She was also commissioner of Health for the City of New York, where she oversaw the first public health bioterrorism preparedness program in the nation.
  • Stephen Albert Johnston, director of the Center for Biomedical Inventions, based in Dallas, has been named a director. He serves as director for a "unique technology development" unit at the Universityof Texas, SouthwesternMedicalCenter. He also conducts basic research into gene regulation, and has served in several research posts with the University of Texas Southwestern Medical Center, DukeUniversity, the Universityof Wisconsinand the US National Institutes of Health.
  • Scott Lillibridge, director of the Center for Biosecurity and Public Health Preparedness, based in Houston, has been named a director. Lillibridge, a professor of epidemiology, was the special assistant for national security and emergency management at the US Department of Health and Human Services. He has also been director of the Bioterrorism Preparedness and Response Program at the Centers for Disease Control and Prevention.
  • C J Peters, director of Biodefense, UTMB Center for Biodefense and Emerging Infectious Diseases, has been named a director. Peters serves as director of Biodefense at the University of Texas Medical Branch and of UTMB's biosafety level 4 laboratory. He is also a member of the World Health Organization Collaborating Center for Tropical Diseases and was a senior official at the CDC.
  • Gen. Dennis J. Reimer (USArmy, Retired), is director of the National Memorial Institute for the Prevention of Terrorism, based in Oklahoma City, Okla.

Pestka Biomedical Laboratories, a manufacturer of interferon reagents for research use, has named Fredric Rhoads as its general manager of the research products group. Rhoades was most recently the vice president of sales and marketing at Ambion, based in Austin, Texas. He has an MBA in marketing and analytical methods from RutgersUniversity.

Compugen has hired Noam Shani as vice president of biology research and development, where he will oversee the Israeli company's drug research and development, and manage therapeutic protein candidate discovery, selection, validation, and preclinical and clinical development.

Shani joins Compugen from Medgenics, where he was vice president of research and development He holds a doctoral degree in biology from the Weizmann Institute of Science, in Israel, and completed a postdoctoral fellowship at Johns Hopkins University's School of Medicine, in Maryland.

Bioinformatics company PointOne Systems has appointed Frank Langley as president and CEO, succeeding Drew Palin. He comes to the company from Pel-Freez Clinical Systems, where he was also president and CEO. Pel-Freez develops molecular biology and serologic products for solid organ and bone marrow transplants.

Langley is currently a director at the Medical College of Wisconsin Research Foundation and the Wisconsin Biotechnology and Medical Device Association.

Teranode has hired Matthew Shanahan chief marketing officer. HE comes to Teranode from Documentum, where he was vice president for the global industries group.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.